14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close May 07, 2026
EKSO vs EXPI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas EXPI carries 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs EXPI. Trailing 12-month operating profitability (EKSO -119.7% vs EXPI -1.1%) and valuation multiples (EKSO N/M vs EXPI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Real Estate Services value chain with $1.0B market capitalization and -1.1% operating margin.
OpEx & R&D Reinvestment8.1% of Rev ($387M)
90D Engineering Disclosures0 Published
Investor FAQ EKSO vs EXPI Key Questions & Quantitative Answers
As of May 07, 2026, eXp World Holdings, Inc. (EXPI) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas EXPI carries 67.2/100 (BUY) at $6.74 (N/M Forward P/E, -1.1% operating margin). Technically, EKSO sits in a Markup phase (RSI 60.4, UNCLASSIFIED options structure) and EXPI sits in a Neutral phase (RSI 59.4, UNCLASSIFIED options structure).
EXPI leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with EXPI at +8.5% YoY revenue growth and +39.8% YoY earnings growth on $4.77B TTM revenue (7.0% gross margin, -1.1% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $4.77B for EXPI. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 8.1% of Rev ($387M) (0 disclosures) for EXPI.
EXPI screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas EXPI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus EXPI (-10.2% ROE) capital efficiency.
In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, EXPI carries 61.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 39% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of May 07, 2026. For educational research only; not investment advice.